← Russell 3000 cross-section

CDRE Cadre Holdings, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$1.3bn
Revenue TTM
$686m
Net income TTM
$36m
Free cash flow
$78m
Composite score
56.5
Sector rank
#1865

Valuation

P / E
37.3
EV / EBITDA
18.3
EV / sales
2.4
FCF yield
5.81%
Earnings yield vs 10-yr
-2.04pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
5.3%
EBITDA margin
13.3%
ROE
10.4%
ROIC
10.3%
Revenue growth
19.7%

Insider activity, last 90 days

Net open-market
$-18.08m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

MANAGEMENT DISCUSSION AND ANALYSIS (in thousands, except share and per share amounts) ​ The following table sets forth a summary of our financial highlights for the periods indicated: Net sales increased by $50.0 million for the three months ended June 30, 2026 as compared to the three months ended June 30, 2025, primarily as a result of current year acquisitions and increased demand for nuclear safety, armor, and duty gear products. …Cadre Holdings, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →